*Otezla significantly increased ACR20 response (n = 168) at week 16 (primary endpoint) vs placebo (n = 168) (38% vs 19%; P = 0.0001)


Otezla significantly increased ACR20 response at week 16 (primary endpoint) vs placebo (38% vs 19%; n = 168 for both; P = 0.0001).1-3

Certain restrictions apply; eligibility not based on income, must be 18 years or older. This offer is not valid for persons eligible for reimbursement of this product, in whole or in part under Medicaid, Medicare, or similar state or federal programs. Offer not valid for cash-paying patients. People who are not eligible can call 1-844-4OTEZLA to discuss other financial assistance opportunities.

References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation. 2. Data on file, Celgene Corporation. 3. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. J Rheumatol. 2015;42(3):479-488.

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a
Healthcare Professional?

For patients who
have commercial insurance,

Getting Otezla

Just Got

Now there are no biologic
agent step-edit requirements

on certain prescription benefit plans.

Call your otezla sales representative
today to learn which plans